公开(公告)号：US07541363B2

公开(公告)日：2009-06-02

申请号：US10554511

申请日：2004-05-07

申请人： Kazutoshi Kuroda ,  Noboru Aoki ,  Toshiro Ochiai ,  Akihiro Uchida ,  Yasuhiro Ishikawa ,  Makoto Kigoshi ,  Eiji Hayakawa ,  Kazuki Asanome

发明人： Kazutoshi Kuroda ,  Noboru Aoki ,  Toshiro Ochiai ,  Akihiro Uchida ,  Yasuhiro Ishikawa ,  Makoto Kigoshi ,  Eiji Hayakawa ,  Kazuki Asanome

IPC分类号： C07D473/06 ,  A61K31/522

CPC分类号： C07D473/06

摘要： Microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione having an average particle size of less than 50 μm; microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione having an average particle size of less than 50 μm and a crystallinity of 20% or more or the like, which possess excellent solubility, stability, bioavailability, dispersing property in a pharmaceutical formulation; and the like are provided. A solid pharmaceutical formulation which is characterized by comprising the same is also provided.

摘要翻译： 平均粒径小于50埃的（E）-8-（3,4-二甲氧基苯乙烯基）-1,3-二乙基-7-甲基-3,7-二氢-1H-嘌呤-2,6-二酮的微晶 妈妈 （E）-8-（3,4-二甲氧基苯乙烯基）-1,3-二乙基-7-甲基-3,7-二氢-1H-嘌呤-2,6-二酮的微晶，平均粒径小于50 具有优异的溶解性，稳定性，生物利用度，药物配方中的分散性的20％以上的结晶度等。 等等。 还提供了其特征在于包含其的固体药物制剂。

公开(公告)号：US20060205745A1

公开(公告)日：2006-09-14

申请号：US10554511

申请日：2004-05-07

申请人： Kazutoshi Kuroda ,  Noboru Aoki ,  Toshiro Ochiai ,  Akihiro Uchida ,  Yasuhiro Ishikawa ,  Makoto Kigoshi ,  Eiji Hayakawa

发明人： Kazutoshi Kuroda ,  Noboru Aoki ,  Toshiro Ochiai ,  Akihiro Uchida ,  Yasuhiro Ishikawa ,  Makoto Kigoshi ,  Eiji Hayakawa

IPC分类号： A61K31/522 ,  C07D473/02

CPC分类号： C07D473/06

摘要： Microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione having an average particle size of less than 50 μm; microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione having an average particle size of less than 50 μm and a crystallinity of 20% or more or the like, which possess excellent solubility, stability, bioavailability, dispersing property in a pharmaceutical formulation; and the like are provided. A solid pharmaceutical formulation which is characterized by comprising the same is also provided.

公开(公告)号：US5142096A

公开(公告)日：1992-08-25

申请号：US329329

申请日：1989-03-27

申请人： Kazutoshi Kuroda ,  Hiroshi Kase ,  Katsuhiko Ando ,  Isao Kawamoto ,  Toru Yasuzawa ,  Hiroshi Sano ,  Joji Goto ,  Koji Yamada

发明人： Kazutoshi Kuroda ,  Hiroshi Kase ,  Katsuhiko Ando ,  Isao Kawamoto ,  Toru Yasuzawa ,  Hiroshi Sano ,  Joji Goto ,  Koji Yamada

IPC分类号： C07C323/20 ,  C07C327/26 ,  C12P7/00

CPC分类号： C07C327/26 ,  C07C323/20 ,  C12P7/00

摘要： KS-506a, KS-506x and KS-506g having an activity to inhibit cyclic nucleotide phosphodiesterase and KS-506m and KS-506h having an activity to inhibit histamine release are produced by culturing a microorganism belonging to the genus Mortierella.

公开(公告)号：US5223637A

公开(公告)日：1993-06-29

申请号：US889388

申请日：1992-05-28

申请人： Kazutoshi Kuroda ,  Hiroshi Kase ,  Katsuhiko Ando ,  Isao Kawamoto ,  Toru Yasuzawa ,  Hiroshi Sano ,  Joji Goto ,  Koji Yamada

发明人： Kazutoshi Kuroda ,  Hiroshi Kase ,  Katsuhiko Ando ,  Isao Kawamoto ,  Toru Yasuzawa ,  Hiroshi Sano ,  Joji Goto ,  Koji Yamada

IPC分类号： C07C323/20 ,  C07C327/26 ,  C12P7/00

CPC分类号： C07C323/20 ,  C07C327/26 ,  C12P7/00

摘要： KS-506a, KS-506x and KS-506g having an activity to inhibit cyclic nucleotide phosphodiesterase and KS-506m and KS-506h having an activity to inhibit histamine release are produced by culturing a microorganism belonging to the genus Mortierella.

摘要翻译： 通过培养属于被孢霉属属的微生物来产生具有抑制环核苷酸磷酸二酯酶的活性的KS-506a，KS-506x和KS-506g以及具有抑制组胺释放活性的KS-506m和KS-506h。